ETRM
Ha hecho un Offering a 0.29 y a la vez anuncia solicitud de autorización para un rs
Estos son valores para seguirlos con muy de cerca con stop muy ajustados y dentro de lo posible profundizar la máximo en sus fundamentales y e intentar conocer lo mas que se pueda las expectativas de mercado del producto que comercializa, la otra opción es a golpe de puro AT pero tenéis que estar 24/24 sobre ella pues al menor descuido te deja con el culo al aire, Dado su delicada situación financiera y el pobre éxito inicial de la comercialización de su equipo para tratamiento de la Obesidad mórbida que no haya podido resolver con los métodos habituales pero que exige un entrenamiento previo a los profesionales que lo van a colocar , las ventas han sido pocas y muy lentas, no obstante varias revistas medico científica han estado recientemente publicando artículos favorables, lo que abría expectativas de largo plazo que no dudo que consiga pero su escaso cash de apenas 14 M/$ , daban miedo para entrar ,
-------
EnteroMedics Announces $25.0 million Registered Direct Offering of Convertible Notes
he Notes will be payable in monthly installments, will accrue interest at a rate of 7.0% per annum from the date of issuance and will mature 24 months after the initial closing. $1.5 million of the Notes will be funded at the initial closing, and the balance will be funded in two tranches of $11.0 million and $12.5 million which are subject to the shareholders of the Company approving a reverse stock split of the Company's common stock and the approval of the issuance of the securities purchased by the Investors. At each issuance, the Notes may be repaid, at the Company's election, in either cash or shares of the Company's common stock at a discount to the then-current market price. The Notes are also convertible from time to time, at the election of the holders, into shares of the Company's common stock at an initial conversion price of $0.29 per share. Additionally, in connection with each issuance of the Notes, the Company will also issue to the investors warrants to purchase a certain number of shares of common stock equal to approximately 30% of the number of shares that would be issued if the principal were converted. The warrants are callable under certain circumstances. The offering is expected to close on or around November 9, 2015.
-----------
The Company intends to hold a Special Shareholder meeting to authorize the Company to carry out a reverse stock split using a conversion ratio within an approved range and to approve the terms of the agreement.
--- http://www.prnewswire.com/news-releases/enteromedics-announces-250-million-registered-direct-offering-of-convertible-notes-300173233.html